[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368310-105":59,"doc-detail-368310-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-pan-tumor-review-of-the-role-of-polyadenosine-diphosphate-ribose-polymerase-inhibitors-review-article","A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors - review article","","Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, including olaparib, talazoparib, rucaparib, and niraparib, are a therapeutic class targeting PARP proteins essential for DNA repair. Tumors with homologous recombination repair defects, especially BRCA alterations, show increased sensitivity via PARP inhibitor–induced synthetic lethality. The review summarizes the evolution of regulatory approvals across malignancies, starting in ovarian cancer and later expanding to breast, pancreatic, and prostate cancer indications, highlighting efficacy from landmark phase 3 trials.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-pan-tumor-review-of-the-role-of-polyadenosine-diphosphate-ribose-polymerase-inhibitors-review-article/368310/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-pan-tumor-review-of-the-role-of-polyadenosine-diphosphate-ribose-polymerase-inhibitors-review-article/368310.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What biological pathway do PARP inhibitors target?","Question",{"text":113,"@type":114},"PARP inhibitors target PARP proteins involved in DNA repair, particularly processes related to single-strand break repair and PARylation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why are PARP inhibitors especially effective in BRCA-altered cancers?",{"text":118,"@type":114},"Cancers with homologous recombination repair defects, particularly BRCA alterations, rely on PARP-mediated repair; inhibiting PARP creates synthetic lethality.",{"name":120,"@type":111,"acceptedAnswer":121},"Which cancers does the review state PARP inhibitors have approvals for?",{"text":122,"@type":114},"The review highlights approvals that began with ovarian cancer and subsequently expanded to breast, pancreatic, and prostate cancers across different indications.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368310,1790198824,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","DOI: 10. 3322/caac.21870  \nREVIEW ARTICLE  \nA pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors  \nChadi Hage Chehade MD1  | Georges Gebrael MD1 | Nicolas Sayegh MD 1,2  | Zeynep Irem Ozay MD 1 | Arshit Narang MBBS1 | Tony Crispino3 |  \nTalia Golan MD4 | Jennifer K. Litton MD5  | Umang Swami MD, MS1 | Kathleen N. Moore MD6 | Neeraj Agarwal MD1  \n1Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA  \n2Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA 3UsTOO Prostate Cancer Support and Education Las Vegas Chapter, Las Vegas, Nevada, USA  \n4Division of Medical Oncology, Sheba Medical Center, Tel Aviv Medical University, Tel Aviv, Israel 5Division of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \n6Division of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma, USA  \nCorrespondence  \nNeeraj Agarwal, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive, Suite 5510, Salt Lake City, UT 84112, USA. Email: [neeraj.agarwal@hci.utah.edu](neeraj.agarwal@hci.utah.edu)  \nAbstract  \nPoly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombination repair defects, particularly BRCA alterations, display enhanced sensitivity to these agents because of synthetic lethality induced by PARP inhibitors. These agents have significantly improved survival outcomes across various malignancies, initially gaining regulatory approval in ovarian cancer and subsequently in breast, pancreatic, and prostate cancers in different indications. This review offers a comprehensive clinical overview of PARP inhibitor approvals, emphasizing their efficacy across different cancers based on landmark phase 3 clinical trials.  \nKEYWORDS  \nbreast cancer, ovarian cancer, pancreatic cancer, poly(adenosine diphosphate ribose) polymerase inhibitors, prostate cancer  \nINTRODUCTION  \nOne of the major pathways in human cancer development and progression is genomic instability, characterized by a high frequency of mutations.1 Typically, human cells attempt to maintain genomic  \nintegrity by using at least five active DNA‐repair pathways: homologous recombination, base excision repair, mismatch repair, nucleotide excision repair, and nonhomologous end joining.2  \nIn the last decade, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors (PARPi) have been approved across  \nChadi Hage Chehade and Georges Gebrael contributed equally to this article.  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.  \n© 2025 The Author(s). CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.  \ndifferent tumor types harboring alterations in homologous recombination. The PARP family includes 17 proteins, and the two major ones involved in single‐strand DNA‐repair mechanisms are PARP1 and PARP2.3 PARP1 binds DNA breaks and forms poly(adenosine diphosphate ribose) (PAR) chains, known as PARylation, which serve as attachment sites for additional repair proteins at the site of DNA damage, facilitating DNA repair. Moreover, the auto‐PARylation of PARP itself promotes its dissociation from the repaired DNA, maintaining the overall genomic stability of the cell.4 PARPi act by trapping PARP1 on DNA and inhibiting normal auto‐PARylation, thus terminating the progression of the replication fork.4 Moreover, the inhibition of PARP1 by PARPi leads to double‐strand breaks,","cbCaiq57Bdj1xoRA","https://ap.wps.com/l/cbCaiq57Bdj1xoRA","pdf",1462289,27,"English","# Introduction\n# Indications in Prostate Cancer\n# Abstract\n# Key Words\n# Mechanism of Action","[{\"question\":\"What biological pathway do PARP inhibitors target?\",\"answer\":\"PARP inhibitors target PARP proteins involved in DNA repair, particularly processes related to single-strand break repair and PARylation.\"},{\"question\":\"Why are PARP inhibitors especially effective in BRCA-altered cancers?\",\"answer\":\"Cancers with homologous recombination repair defects, particularly BRCA alterations, rely on PARP-mediated repair; inhibiting PARP creates synthetic lethality.\"},{\"question\":\"Which cancers does the review state PARP inhibitors have approvals for?\",\"answer\":\"The review highlights approvals that began with ovarian cancer and subsequently expanded to breast, pancreatic, and prostate cancers across different indications.\"}]","A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors - review article | PDF",1790176187,68,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf445ea54fd78f3c90dc8e56ba93e322.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c12b4f4d58712d18c43df0663cd9cbd8.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03ccc99817f82c145e0080231f9a3d71.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13d21d33a38fdcec6600327bb3bf1f38.webp",980,1287]